Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203080 | 0.85 | MAPT (0.58) | MAPTHPGDRECQLSMN1; SMN2HTT | |
| SCHEMBL7393022 | 0.79 | MAPT (0.55) | MAPTHPGDRECQLSMN1; SMN2HTT | |
| SCHEMBL3509692 | 0.78 | MAPT (0.60) | MAPTHPGDRECQLSMN1; SMN2HTT | |
| SCHEMBL7393998 | 0.78 | DRD3 (0.51) | MAPTHPGDRECQLSMN1; SMN2HTT | |
| SCHEMBL2068948 | 0.77 | MAPT (0.55) | MAPTHPGDRECQLSMN1; SMN2HTT | |
| SCHEMBL27367412 | 0.77 | MAPT (1.00) | MAPTHPGDSMN1; SMN2HTTKMT2A | |
| SCHEMBL15504862 | 0.76 | MAPT (0.82) | MAPTHPGDSMN1; SMN2HTTKMT2A | |
| SCHEMBL6870725 | 0.74 | MAPT (0.59) | MAPTHPGDRECQLSMN1; SMN2HTT | |
| SCHEMBL27367418 | 0.73 | MAPK1 (0.78) | MAPTHPGDSMN1; SMN2HTTKMT2A | |
| SCHEMBL2070345 | 0.73 | MAPT (0.51) | MAPTHPGDRECQLSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079901-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8703759-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-0237467-B1 | HETEROARYL-OXY-BETA-CARBOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-10-28 | — | — | EP | disclosed |
| EP-0282502-B1 | IMIDAZOLE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-05-15 | — | — | EP | disclosed |
| US-4960777-A | Anxiolytic agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | disclosed |
| US-4952698-A | Imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-08-28 | — | — | US | disclosed |
| US-4877792-A | ANXIOLYTIC AGENTS; ANTICONVULSANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | MAPT 4213/4885HPGD 1333/4885RECQL 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.